<p>Highland Capital Management LLC 在第二季度減持了 Jazz Pharmaceuticals plc（納斯達克股票代碼：JAZZ - 免費報告）的持股比例，根據該公司最近向證券交易委員會提交的 13F 申報。該基金在本季度賣出 2,480 股後，持有這家專業製藥公司的股票 29,990 股。Highland Capital Management LLC 在最新的提交給證券交易委員會的申報中，持有的 Jazz Pharmaceuticals 股份價值 3,201,000 美元。</p>
<p>獲取 Jazz Pharmaceuticals 的警報：</p>
<ul>
<li>Zymeworks 為不僅僅是長期投資者帶來希望</li>
</ul>
<p>一些其他對沖基金最近也調整了他們對 JAZZ 的持股。Rise Advisors LLC 在第一季度將其在 Jazz Pharmaceuticals 的持倉增加了 2,255.6%。Rise Advisors LLC 現在擁有 212 股這家專業製藥公司的股票，價值 26,000 美元，在該期間又增持了 203 股。Versant Capital Management Inc 在第二季度增加了其在 Jazz Pharmaceuticals 的持股量 13,450.0%。Versant Capital Management Inc 現在擁有 271 股這家專業製藥公司的股票，價值 29,000 美元，在上個季度購入了 269 股。GAMMA Investing LLC 在第二季度增加了其在 Jazz Pharmaceuticals 的持股 65.5%。GAMMA Investing LLC 現在擁有 293 股這家專業製藥公司的股票，價值 31,000 美元，在該期間購入了 116 股。Gladius Capital Management LP 在第二季度購入了 Jazz Pharmaceuticals 的新股份，價值約 33,000 美元。最後，Cape Investment Advisory Inc.在第四季度將其在 Jazz Pharmaceuticals 的持股增加了 14,600.0%。Cape Investment Advisory Inc.現在擁有 294 股這家專業製藥公司的股票，價值 36,000 美元，在該期間購入了 292 股。對沖基金和其他機構投資者擁有公司股份的 89.14%。</p>
<h2>華爾街分析師觀點</h2>
<p>一些研究分析師對這支股票發表了意見。加拿大皇家銀行將 Jazz Pharmaceuticals 的目標股價從 175.00 美元降至 174.00 美元，併為該公司設定了 “表現優異” 的評級，日期為 2019 年 8 月 1 日。康泰菲茲傑拉德重申了對 Jazz Pharmaceuticals 的 “超重” 評級，並在 2019 年 8 月 1 日的一份報告中給出了 140.00 美元的價格目標。StockNews.com 將 Jazz Pharmaceuticals 的股票評級從 “買入” 提升為 “強烈買入”，日期為 2019 年 8 月 1 日。摩根大通將 Jazz Pharmaceuticals 的目標股價從 190.00 美元提高至 202.00 美元，並在 2019 年 8 月 19 日的一份研究報告中給予該公司 “超重” 評級。最後，HC Wainwright 重申了對 Jazz Pharmaceuticals 的 “買入” 評級，並設定了 200.00 美元的價格目標，日期為 2019 年 8 月 1 日。四位股票研究分析師對該股票進行了持有評級，十一位給出了買入評級，一位給出了強烈買入評級。根據 MarketBeat.com 的數據，該公司目前的一致評級為 “中等買入”，目標股價為 173.07 美元。</p>
<p>查看我們對 JAZZ 的最新股票分析</p>
<h2>Jazz Pharmaceuticals 股票表現</h2>
<p>JAZZ 股票週一開盤價為 114.73 美元。該股票的 50 天移動平均價格為 109.11 美元，200 天移動平均價格為 112.99 美元。該公司的資產負債比為 1.36，速動比率為 1.90，流動比率為 2.37。Jazz Pharmaceuticals plc 的一年最低價為 99.06 美元，一年最高價為 146.70 美元。該公司的市值為 72.4 億美元，市盈率為 23.48，PEG 比為 1.76，貝塔係數為 0.58。</p>
<h2>Jazz Pharmaceuticals 簡介（免費報告）</h2>
<p>Jazz Pharmaceuticals plc 在美國、歐洲和國際市場確定、開發和銷售滿足醫療需求的藥品。該公司提供 Xywav 用於猝倒或白天過度嗜睡（EDS）伴有睡病和特發性嗜睡症；Xyrem 用於治療猝倒或白天過度嗜睡伴有睡病；Epidiolex 用於與 Lennox-Gastaut 綜合徵、Dravet 綜合徵或結節硬化複雜相關的癲癇發作；Zepzelca 用於治療轉移性小細胞肺癌，或在鉑類化療後疾病進展；Rylaze 用於急性淋巴細胞白血病或淋巴細胞淋巴瘤；Enrylaze 用於治療急性淋巴細胞白血病和淋巴細胞淋巴瘤；Defitelio 用於治療嚴重肝靜脈閉塞性疾病；Vyxeos 用於新診斷的治療相關急性髓系白血病。</p>
<h2>進一步閲讀</h2>
<ul>
<li>五支我們比 Jazz Pharmaceuticals 更喜歡的股票</li>
<li>房地產投資信託股票 - 今天添加到您的投資組合的最佳房地產投資信託股票</li>
<li>艾禮禮制藥通往下一個萬億市值之路</li>
<li>在 52 周最低點找到並有利可圖地交易股票</li>
<li>Mobileye Global：首席執行官對未來實力進行 1000 萬美元的押注</li>
<li>上海證券交易所綜合指數是什麼？</li>
<li>3 支在降息之前增加股息支付的股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SkFaWg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SkFaWg"/></p>
<p><em>這則即時新聞警報是由 MarketBeat 的敍事科技和金融數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊的審查。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<p>→ 唯一值得購買的人工智能公司（由波特和公司提供）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04ODY2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04ODY2"/></p>
<h2>您現在是否應該投資 1,000 美元購買 Jazz Pharmaceuticals 股票？</h2>
<p>在考慮購買 Jazz Pharmaceuticals 股票之前，您需要聽到這個。</p>
<p>MarketBeat 追蹤華爾街評級最高、表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴他們的客户現在應該購買的股票，然後再更廣泛市場關注之前...而爵士製藥並不在這份名單上。</p>
<p>儘管爵士製藥目前在分析師中擁有 “中等買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

爵士制藥

<p>高原資本管理有限責任公司在第二季度減持了爵士製藥（Jazz Pharmaceuticals plc，NASDAQ: JAZZ）的股份，根據最近的 13F 申報，減持了 7.6%。在出售了 2,480 股後，他們現在持有 29,990 股，價值 201,000 美元。其他對沖基金也調整了他們的持股，顯示出對爵士製藥周圍有顯着的活動。分析師對該股的評級褒貶不一，但共識仍然是 “中度買入”，目標價為 118.07 美元。該股的表現顯示市值為 62.4 億美元，在過去一年內的交易價格介於 54.06 美元和 70.70 美元之間</p>

<p>Highland Capital Management LLC decreased its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 7.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 29,990 shares of the specialty pharmaceutical company's stock after selling 2,480 shares during the quarter. Highland Capital Management LLC's holdings in Jazz Pharmaceuticals were worth $3,201,000 as of its most recent filing with the Securities and Exchange Commission.</p>
<div class="lb-trans"><p>Highland Capital Management LLC 在第二季度減持了 Jazz Pharmaceuticals plc（納斯達克股票代碼：JAZZ - 免費報告）的持股比例，根據該公司最近向證券交易委員會提交的 13F 申報。該基金在本季度賣出 2,480 股後，持有這家專業製藥公司的股票 29,990 股。Highland Capital Management LLC 在最新的提交給證券交易委員會的申報中，持有的 Jazz Pharmaceuticals 股份價值 3,201,000 美元。</p>
</div><p>Get <strong>Jazz Pharmaceuticals</strong> alerts:</p>
<ul>
<li>Zymeworks Offers Hope for More than Just Long-Term Investors</li>
</ul>
<div class="lb-trans"><p>獲取 Jazz Pharmaceuticals 的警報：</p>
<ul>
<li>Zymeworks 為不僅僅是長期投資者帶來希望</li>
</ul>
</div><p>A number of other hedge funds have also recently modified their holdings of JAZZ. Rise Advisors LLC grew its position in Jazz Pharmaceuticals by 2,255.6% in the first quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company's stock worth $26,000 after acquiring an additional 203 shares during the period. Versant Capital Management Inc lifted its stake in shares of Jazz Pharmaceuticals by 13,450.0% in the 2nd quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company's stock valued at $29,000 after purchasing an additional 269 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Jazz Pharmaceuticals by 65.5% during the 2nd quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company's stock worth $31,000 after purchasing an additional 116 shares during the period. Gladius Capital Management LP acquired a new stake in shares of Jazz Pharmaceuticals during the 2nd quarter worth about $33,000. Finally, Cape Investment Advisory Inc. raised its holdings in Jazz Pharmaceuticals by 14,600.0% in the 4th quarter. Cape Investment Advisory Inc. now owns 294 shares of the specialty pharmaceutical company's stock valued at $36,000 after buying an additional 292 shares during the period. Hedge funds and other institutional investors own 89.14% of the company's stock.</p>
<div class="lb-trans"><p>一些其他對沖基金最近也調整了他們對 JAZZ 的持股。Rise Advisors LLC 在第一季度將其在 Jazz Pharmaceuticals 的持倉增加了 2,255.6%。Rise Advisors LLC 現在擁有 212 股這家專業製藥公司的股票，價值 26,000 美元，在該期間又增持了 203 股。Versant Capital Management Inc 在第二季度增加了其在 Jazz Pharmaceuticals 的持股量 13,450.0%。Versant Capital Management Inc 現在擁有 271 股這家專業製藥公司的股票，價值 29,000 美元，在上個季度購入了 269 股。GAMMA Investing LLC 在第二季度增加了其在 Jazz Pharmaceuticals 的持股 65.5%。GAMMA Investing LLC 現在擁有 293 股這家專業製藥公司的股票，價值 31,000 美元，在該期間購入了 116 股。Gladius Capital Management LP 在第二季度購入了 Jazz Pharmaceuticals 的新股份，價值約 33,000 美元。最後，Cape Investment Advisory Inc.在第四季度將其在 Jazz Pharmaceuticals 的持股增加了 14,600.0%。Cape Investment Advisory Inc.現在擁有 294 股這家專業製藥公司的股票，價值 36,000 美元，在該期間購入了 292 股。對沖基金和其他機構投資者擁有公司股份的 89.14%。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>Several research analysts have weighed in on the stock. Royal Bank of Canada lowered their target price on shares of Jazz Pharmaceuticals from $175.00 to $174.00 and set an &#34;outperform&#34; rating for the company in a research note on Thursday, August 1st. Cantor Fitzgerald restated an &#34;overweight&#34; rating and issued a $140.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, August 1st. StockNews.com raised shares of Jazz Pharmaceuticals from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research report on Thursday, August 1st. JPMorgan Chase &amp; Co. boosted their target price on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an &#34;overweight&#34; rating in a research report on Monday, August 19th. Finally, HC Wainwright restated a &#34;buy&#34; rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, August 1st. Four equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $173.07.</p>
<ul>
<li>Top Marijuana Stocks: Plenty of Investment Opportunities Abound (You're not Late to the Game)</li>
</ul>
<div class="lb-trans"><p>一些研究分析師對這支股票發表了意見。加拿大皇家銀行將 Jazz Pharmaceuticals 的目標股價從 175.00 美元降至 174.00 美元，併為該公司設定了 “表現優異” 的評級，日期為 2019 年 8 月 1 日。康泰菲茲傑拉德重申了對 Jazz Pharmaceuticals 的 “超重” 評級，並在 2019 年 8 月 1 日的一份報告中給出了 140.00 美元的價格目標。StockNews.com 將 Jazz Pharmaceuticals 的股票評級從 “買入” 提升為 “強烈買入”，日期為 2019 年 8 月 1 日。摩根大通將 Jazz Pharmaceuticals 的目標股價從 190.00 美元提高至 202.00 美元，並在 2019 年 8 月 19 日的一份研究報告中給予該公司 “超重” 評級。最後，HC Wainwright 重申了對 Jazz Pharmaceuticals 的 “買入” 評級，並設定了 200.00 美元的價格目標，日期為 2019 年 8 月 1 日。四位股票研究分析師對該股票進行了持有評級，十一位給出了買入評級，一位給出了強烈買入評級。根據 MarketBeat.com 的數據，該公司目前的一致評級為 “中等買入”，目標股價為 173.07 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on JAZZ</strong></p>
<div class="lb-trans"><p>查看我們對 JAZZ 的最新股票分析</p>
</div><h2>Jazz Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Jazz Pharmaceuticals 股票表現</h2>
</div><p>Shares of JAZZ stock opened at $114.73 on Monday. The stock's 50-day moving average is $109.11 and its two-hundred day moving average is $112.99. The company has a debt-to-equity ratio of 1.36, a quick ratio of 1.90 and a current ratio of 2.37. Jazz Pharmaceuticals plc has a 1 year low of $99.06 and a 1 year high of $146.70. The firm has a market cap of $7.24 billion, a price-to-earnings ratio of 23.48, a PEG ratio of 1.76 and a beta of 0.58.</p>
<div class="lb-trans"><p>JAZZ 股票週一開盤價為 114.73 美元。該股票的 50 天移動平均價格為 109.11 美元，200 天移動平均價格為 112.99 美元。該公司的資產負債比為 1.36，速動比率為 1.90，流動比率為 2.37。Jazz Pharmaceuticals plc 的一年最低價為 99.06 美元，一年最高價為 146.70 美元。該公司的市值為 72.4 億美元，市盈率為 23.48，PEG 比為 1.76，貝塔係數為 0.58。</p>
</div><h2>Jazz Pharmaceuticals Profile (Free Report)</h2>
<div class="lb-trans"><h2>Jazz Pharmaceuticals 簡介（免費報告）</h2>
</div><p>Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.</p>
<div class="lb-trans"><p>Jazz Pharmaceuticals plc 在美國、歐洲和國際市場確定、開發和銷售滿足醫療需求的藥品。該公司提供 Xywav 用於猝倒或白天過度嗜睡（EDS）伴有睡病和特發性嗜睡症；Xyrem 用於治療猝倒或白天過度嗜睡伴有睡病；Epidiolex 用於與 Lennox-Gastaut 綜合徵、Dravet 綜合徵或結節硬化複雜相關的癲癇發作；Zepzelca 用於治療轉移性小細胞肺癌，或在鉑類化療後疾病進展；Rylaze 用於急性淋巴細胞白血病或淋巴細胞淋巴瘤；Enrylaze 用於治療急性淋巴細胞白血病和淋巴細胞淋巴瘤；Defitelio 用於治療嚴重肝靜脈閉塞性疾病；Vyxeos 用於新診斷的治療相關急性髓系白血病。</p>
</div><h2>Further Reading</h2>
<ul>
<li>Five stocks we like better than Jazz Pharmaceuticals</li>
<li>REIT Stocks - Best REIT Stocks to Add to Your Portfolio Today</li>
<li>Eli Lilly’s Path to the Next Trillion Market Capitalization</li>
<li>Find and Profitably Trade Stocks at 52-Week Lows</li>
<li>Mobileye Global: CEO Makes $10 Million Bet on Future Strength</li>
<li>What is the Shanghai Stock Exchange Composite Index?</li>
<li>3 Stocks Increasing Dividend Payouts Ahead of Interest Rate Cuts</li>
</ul>
<div class="lb-trans"><h2>進一步閲讀</h2>
<ul>
<li>五支我們比 Jazz Pharmaceuticals 更喜歡的股票</li>
<li>房地產投資信託股票 - 今天添加到您的投資組合的最佳房地產投資信託股票</li>
<li>艾禮禮制藥通往下一個萬億市值之路</li>
<li>在 52 周最低點找到並有利可圖地交易股票</li>
<li>Mobileye Global：首席執行官對未來實力進行 1000 萬美元的押注</li>
<li>上海證券交易所綜合指數是什麼？</li>
<li>3 支在降息之前增加股息支付的股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SkFaWg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=JAZZ"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>這則即時新聞警報是由 MarketBeat 的敍事科技和金融數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊的審查。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><p>→ The only AI company to buy (From Porter &amp; Company)(Ad)</p>
<div class="lb-trans"><p>→ 唯一值得購買的人工智能公司（由波特和公司提供）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04ODY2" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8866&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Jazz Pharmaceuticals right now?</h2>
<div class="lb-trans"><h2>您現在是否應該投資 1,000 美元購買 Jazz Pharmaceuticals 股票？</h2>
</div><p>Before you consider Jazz Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮購買 Jazz Pharmaceuticals 股票之前，您需要聽到這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Jazz Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追蹤華爾街評級最高、表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴他們的客户現在應該購買的股票，然後再更廣泛市場關注之前...而爵士製藥並不在這份名單上。</p>
</div><p>While Jazz Pharmaceuticals currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管爵士製藥目前在分析師中擁有 “中等買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Highland Capital Management LLC 減少了在爵士製藥公司（NASDAQ:JAZZ）的持倉